FindTrial
Sign In

Hydroxychloroquine Efficacy on Behcet's Disease Thrombosis

The Efficacy of Hydroxychloroquine on Behcet's Disease Thrombotic Events Prevention

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04022421
Enrollment
50
Registered
2019-07-17
Start date
2018-10-01
Completion date
2019-10-31
Last updated
2019-07-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Behcet's Syndrome, Vascular Type

Brief summary

Patients diagnosed with Behcet's disease will be randomized to administeration of hydroxychloroquine. Assessment will be done for the patients at baseline and every one month in the first three months and then quarterly for one year.

Interventions

DRUGHydroxychloroquine

the drug will be taken by one group of the patients daily at a dose of 400mg

Sponsors

Assiut University
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* All patients diagnosed with Behcet's disease on any DMARDs

Exclusion criteria

* Patients with critical conditions * Patients with hypersensitivity or adverse drug reactions to hydroxychloroquine.

Design outcomes

Primary

MeasureTime frameDescription
Prevention of the recurrence of thrombotic events6 months- one yearnumber of relapses is expected to fall with the longterm use of the drug

Countries

Egypt

Contacts

Primary ContactAlaa Mohamed, Post-doctor
a.a.a.mohamed@aun.edu.eg+20882413177

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026